Head-to-head · WeighScore
LevelUp Rx vs Omada Health
The verdict
LevelUp Rx takes it — 64.4/100 to 55.6/100.
LevelUp Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. LevelUp Rx is a telehealth pharmacy offering compounded GLP-1 weight-loss medications - compounded semaglutide and compounded tirzepatide - alongside a broad menu of men's and women's health treatments.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | LevelUp Rx | Omada Health |
|---|---|---|
| WeighScore | 64.4/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #239 | #435 |
| Semaglutide | $150/mo (starting dose, compounded) | Not disclosed |
| Tirzepatide | $250/mo (starting dose, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #239 · C
Strengths
- Compounded semaglutide ($149.97/mo) and tirzepatide ($249.97/mo) on one platform
- Flat monthly price that never changes with your dose
- No-cost online consultation included with your order
- LegitScript-certified; partner pharmacies named (DiRx and The DrugStore)
- Free shipping with no insurance required
Where it loses points
- Compounded only - no brand-name Wegovy, Zepbound, Ozempic or Mounjaro
- No single prescribing medical group named; physicians listed only for CA, MA, RI and VT
- State availability is confirmed during intake, not published as a list
- Prescription sales are final once shipped; no returns on dispensed medication
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.